v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 18 Months Ended
Feb. 01, 2026
Jan. 26, 2025
Feb. 01, 2026
Jan. 26, 2025
Feb. 01, 2026
Cash flows from operating activities:          
Net earnings $ 145 $ 173 $ 339 $ 391  
Adjustments to reconcile net earnings to operating cash flow          
Impairment charges 0 26 [1] 0 26 [1]  
Restructuring charges [2] 3 5 6 11  
Stock-based compensation     33 36  
Pension and postretirement benefit expense (income)     (2) 2  
Depreciation and amortization 102 110 201 219  
Deferred income taxes     40 5  
Loss on sale of business [3] 0 0 0 25  
Other     63 67  
Changes in working capital, net of divestitures          
Accounts receivable     (94) (94)  
Inventories     64 52  
Other current assets     (30) (24)  
Accounts payable and accrued liabilities     137 40  
Other     (17) (19)  
Net cash provided by operating activities     740 737  
Cash flows from investing activities:          
Purchases of plant assets     (227) (211)  
Purchases of routes     (56) (90)  
Sales of routes     45 61  
Sales of businesses     5 70  
Other     (1) (5)  
Net cash used in investing activities     (234) (175)  
Cash flows from financing activities:          
Short-term borrowings, including commercial paper     1,039 663  
Short-term repayments, including commercial paper     (1,387) (925)  
Long-term borrowings     549 1,144  
Long-term repayments     0 (400)  
Dividends paid     (237) (227)  
Treasury stock purchases     (26) (56)  
Payments related to tax withholding for stock-based compensation     (11) (28)  
Payments of debt issuance costs     (5) (11)  
Net cash provided by (used in) financing activities     (78) 160  
Effect of exchange rate changes on cash     1 (1)  
Net change in cash and cash equivalents     429 721  
Cash and cash equivalents - beginning of period     132 108 $ 108
Cash and cash equivalents - end of period $ 561 $ 829 $ 561 $ 829 $ 561
[1] In the second quarter of 2025, we recognized an impairment charge of $15 million on our Allied brands trademarks and an impairment charge of $11 million on our Late July trademark.
[2] See Note 8 for additional information.
[3] See Note 4 for additional information.